Tag: Pe treatment

According to the CDC, up to 900,000 Americans are affected by blood clots each year, with pulmonary embolisms being a potentially fatal complication. A critical question for many patients is, "Do blood thinners break up pulmonary embolisms?" While the term is misleading, the answer is no; their primary role is to stop existing clots from enlarging and to prevent new ones from forming, allowing the body's natural processes to do the work.

While it's a common misconception, the drug ELIQUIS (apixaban) does not actively dissolve existing blood clots. Instead, it works as an anticoagulant, stopping clots from growing larger and preventing new ones from forming, giving the body's own system time to break down the blockage naturally.

According to treatment guidelines from the American Society of Hematology, both Eliquis (apixaban) and Xarelto (rivaroxaban) are considered first-choice treatments for pulmonary embolism (PE). The decision of "is ELIQUIS or Xarelto better for PE?" ultimately depends on an individual patient's specific health factors, risk profiles, and lifestyle preferences.

The U.S. Food and Drug Administration (FDA) approved XARELTO (rivaroxaban) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in 2012, marking a significant advancement in anticoagulant therapy. This oral medication offers a convenient and effective option for managing these dangerous blood clots. This guide details how **Can XARELTO be used for PE**, outlining its mechanism, effectiveness, and key safety information for patients and caregivers.

According to the CDC, pulmonary embolism (PE) affects up to 900,000 Americans each year, with approximately one-third of these events resulting in death. While well-established treatments exist, recent innovations are pushing boundaries for safer and more effective care, which begs the question: What is the new medication for PE?